Lakhasly

iterature Review

Introduction Major Depressive Disorder (MDD) is a common psychiatric condition worldwide, causing substantial morbidity, impaired functioning, and increased suicide risk.Clinical Evidence Clinical studies and randomized trials show rapid antidepressant effects of intravenous ketamine in TRD patients, with significant improvements over placebo, highlighting its potential as an innovative treatment (8,9).Ketamine as a Novel Antidepressant Ketamine, an NMDA receptor antagonist used in anesthesia, shows rapid antidepressant effects by modulating glutamate and enhancing synaptic connectivity.Conventional antidepressants target monoamines (serotonin, norepinephrine) but have delayed onset and limited efficacy in many patients, highlighting the need for alternative therapies (2,3).Body

treatment-resistent depression and limitation of conventional therapies TRD is defined as the lack of response to at least two adequate antidepressant trials.Dysregulated glutamatergic neurotransmission, impaired synaptic plasticity, and altered neurotrophic signaling are key contributors.This boosts thoughts-derived neurotrophic factor (BDNF) and promotes synaptic plasticity in temper-related thoughts regions (7).

iterature Review

Introduction
Major Depressive Disorder (MDD) is a common psychiatric condition worldwide, causing substantial morbidity, impaired functioning, and increased suicide risk. Many patients fail to achieve full remission despite multiple treatments, especially those with treatment-resistant depression (TRD). This has driven research into novel, rapid-acting therapies such as ketamine (1,2).

Body

treatment-resistent depression and limitation of conventional therapies
TRD is defined as the lack of response to at least two adequate antidepressant trials. Patients often experience chronic symptoms, poor quality of life, and high healthcare use. Conventional antidepressants target monoamines (serotonin, norepinephrine) but have delayed onset and limited efficacy in many patients, highlighting the need for alternative therapies (2,3).

Neurobiology of Depression and Glutamate
Depression involves extra than monoamine deficiency. Dysregulated glutamatergic neurotransmission, impaired synaptic plasticity, and altered neurotrophic signaling are key contributors. Glutamate, the number one excitatory neurotransmitter, is critical for synaptic plasticity and mood regulation, making it a promising purpose for novel antidepressants (4,5).
Ketamine as a Novel Antidepressant
Ketamine, an NMDA receptor antagonist used in anesthesia, shows rapid antidepressant effects by modulating glutamate and enhancing synaptic connectivity. Improvements can occur within hours, unlike conventional antidepressants (6,8).

Mechanism of Action
Ketamine blocks NMDA receptors, increasing glutamate release and activating AMPA receptors. This boosts thoughts-derived neurotrophic factor (BDNF) and promotes synaptic plasticity in temper-related thoughts regions (7).
Clinical Evidence
Clinical studies and randomized trials show rapid antidepressant effects of intravenous ketamine in TRD patients, with significant improvements over placebo, highlighting its potential as an innovative treatment (8,9).

Safety Considerations
Limitations embody short duration of effect, dissociation, psychotomimetic symptoms, and functionality misuse. Long-term safety remains under study, requiring optimized dosing and monitoring (10).
Conclusion
MDD, especially TRD, remains a major health challenge.Limitations of conventional antidepressants have driven research into glutamatergic mechanisms.. Ketamine offers rapid, clinically supported antidepressant effects, but safety and durability issues require further research to optimize long-term outcomes.